Status:
COMPLETED
Rosiglitazone Versus Theophylline in Asthmatic Smokers
Lead Sponsor:
University of Glasgow
Collaborating Sponsors:
GlaxoSmithKline
Chest, Heart and Stroke Association Scotland
Conditions:
Asthma
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
Asthmatic smokers display a blunted response to both inhaled and oral corticosteroid treatments and are at increased risk for exacerbations and near fatal asthma. The prevalence of smoking in asthmati...
Detailed Description
Smoking asthmatics have chronic pulmonary inflammation that is relatively steroid resistant. PPAR agonists (of which rosiglitazone is one example) have been shown to reduce several markers of inflamma...
Eligibility Criteria
Inclusion
- Males or females between 18 and 60 years of age (inclusive).
- Clinical diagnosis of mild or moderate persistent asthma in accordance with the Global Initiative for Asthma (GINA) criteria
- Have had a history of asthma for a minimum of 6 months prior to entry into the study
- Subjects must be current cigarette smokers with a minimum five-pack-year smoking history
- Baseline FEV1 that is greater than 50% predicted; and reversibility of 12% or more at screening, washout or randomisation.
- Capable of providing signed written informed consent and complying with all the specified study procedures.
Exclusion
- Asthma exacerbation or a respiratory tract infection within four weeks of screening.
- Type 1 or type 2 diabetes mellitus.
- Women who are lactating, pregnant, or planning to become pregnant.
- Clinically significant renal or hepatic laboratory values (e.g. AST/ALT/total bilirubin/AP \> 2.5 times normal values).
- Anaemia (\< 11 g/dL for males or \< 10 g/dL for females)
- Contraindications to treatment as outlined in any of the product labels
- Prior history of severe oedema or serious fluid related event (e.g., heart failure) associated with any TZD
- The subject has a history of significant hypersensitivity to study drugs
- Presence of unstable or severe angina or congestive heart failure (NYHA class III/IV) or evidence or history of known congestive heart failure (NYHA class I-IV) or an abnormal electrocardiogram (ECG), as determined by the Investigator, or subjects who have had new cardiac events (such as MI, new CHF, PTCA, CABG) within 6 months of screening.
- History or suspicion of current drug abuse or alcohol abuse within the last 6 months.
- History suggestive of active infection or non-asthma lung pathology
- Clinically significant renal disease, metabolic syndrome, cirrhosis (Child-Pugh Class B/C), hypertension or any other clinically significant cardiovascular, neurological, endocrine, or haematological abnormalities that are uncontrolled on permitted therapy.
- Risk factors for human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection at Screening (Visit 1)
- Subjects who are morbidly obese, defined as having a body mass index (BMI) \> 40 kg/m2
- Unable to perform spirometry
- Subjects who require treatment with any of the following asthma medications from Screening (Visit 1) until study completion:
- Inhaled cromolyn sodium or nedocromil;
- Ipratropium bromide;
- Xanthines (theophylline preparations);
- Leukotriene modifiers;
- Long-acting inhaled beta2-agonists (salmeterol, formoterol);
- Oral beta2-agonists.
- Treatment with oral, intravenous or intra-articular corticosteroids within 6 weeks of Screening or thereafter.
- Subjects who have been taking in excess of 1000 μg daily of beclomethasone (or equivalent) within 6 weeks of Screening
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT00119496
Start Date
July 1 2005
End Date
June 1 2007
Last Update
January 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asthma Research Group, Gartnavel General Hospital
Glasgow, Scotland, United Kingdom, G12 0YN